Evaluation of a Prediction Model for the Development of Atrial Fibrillation in a Repository of Electronic Medical Records.

Importance Atrial fibrillation (AF) contributes to substantial morbidity, mortality, and health care expenditures. Accurate prediction of incident AF would enhance AF management and potentially improve patient outcomes. Objective To validate the AF risk prediction model originally developed by the Cohorts for Heart and Aging Research in Genomic Epidemiology-Atrial Fibrillation (CHARGE-AF) investigators using a large repository of electronic medical records (EMRs). Design, Setting, and Participants In this prediction model study, deidentified EMRs of 33 494 individuals 40 years or older who were white or African American and had no history of AF were reviewed and analyzed. The participants were followed up in the internal medicine outpatient clinics at Vanderbilt University Medical Center for incident AF from December 31, 2005, until December 31, 2010. Adjusting for differences in baseline hazard, the CHARGE-AF Cox proportional hazards model regression coefficients were applied to the EMR cohort. A simple version of the model with no echocardiographic variables was also evaluated. Data were analyzed from October 31, 2013, to January 31, 2014. Main Outcomes and Measures Incident AF. Predictors in the model included age, race, height, weight, systolic and diastolic blood pressure, treatment for hypertension, smoking status, type 2 diabetes, heart failure, history of myocardial infarction, left ventricular hypertrophy, and PR interval. Results Among the 33 494 participants, the median age was 57 (interquartile range, 49-67) years; 57% of patients were women, 43% were men, 85.7% were white, and 14.3% were African American. During the mean (SD) follow-up of 4.8 (0.9) years, 2455 individuals (7.3%) developed AF. Both models had poor calibration in the EMR cohort, with underprediction of AF among low-risk individuals and overprediction of AF among high-risk individuals (10th and 90th percentiles for predicted probability of incident AF, 0.005 and 0.179, respectively). The full CHARGE-AF model had a C index of 0.708 (95% CI, 0.699-0.718) in our cohort. The simple model had similar discrimination (C index, 0.709; 95% CI, 0.699-0.718; P = .70 for difference between models). Conclusions and Relevance Despite reasonable discrimination, the CHARGE-AF models showed poor calibration in this EMR cohort. This study highlights the difficulties of applying a risk model derived from prospective cohort studies to an EMR cohort and suggests that these AF risk prediction models be used with caution in the EMR setting. Future risk models may need to be developed and validated within EMR cohorts.

[1]  N. Roetker,et al.  Prediction of Atrial Fibrillation in a Racially Diverse Cohort: The Multi‐Ethnic Study of Atherosclerosis (MESA) , 2016, Journal of the American Heart Association.

[2]  R. Luben,et al.  Performance of the CHARGE-AF risk model for incident atrial fibrillation in the EPIC Norfolk cohort , 2015, European journal of preventive cardiology.

[3]  Lowering blood pressure in patients with diabetes--reply. , 2015, JAMA.

[4]  C. Murray,et al.  Worldwide Epidemiology of Atrial Fibrillation: A Global Burden of Disease 2010 Study , 2014, Circulation.

[5]  Kevin B. Johnson,et al.  Electronic health record design and implementation for pharmacogenomics: a local perspective , 2013, Genetics in Medicine.

[6]  Melissa A. Basford,et al.  Validation of electronic medical record-based phenotyping algorithms: results and lessons learned from the eMERGE network. , 2013, Journal of the American Medical Informatics Association : JAMIA.

[7]  David D. McManus,et al.  Simple Risk Model Predicts Incidence of Atrial Fibrillation in a Racially and Geographically Diverse Population: the CHARGE‐AF Consortium , 2013, Journal of the American Heart Association.

[8]  Hongfang Liu,et al.  A Study of Transportability of an Existing Smoking Status Detection Module across Institutions , 2012, AMIA.

[9]  Melissa A. Basford,et al.  Optimizing Drug Outcomes Through Pharmacogenetics: A Case for Preemptive Genotyping , 2012, Clinical pharmacology and therapeutics.

[10]  G. Lip,et al.  New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper. , 2012, Journal of the American College of Cardiology.

[11]  H. Calkins Catheter ablation to maintain sinus rhythm. , 2012, Circulation.

[12]  M. Woodward,et al.  Risk prediction models: II. External validation, model updating, and impact assessment , 2012, Heart.

[13]  Suzette J. Bielinski,et al.  Use of diverse electronic medical record systems to identify genetic risk for type 2 diabetes within a genome-wide association study , 2012, J. Am. Medical Informatics Assoc..

[14]  S. Johnston,et al.  Estimation of Total Incremental Health Care Costs in Patients With Atrial Fibrillation in the United States , 2011, Circulation. Cardiovascular quality and outcomes.

[15]  Yu Wang,et al.  The Role of Renin–Angiotensin System Blockade Therapy in the Prevention of Atrial Fibrillation: A Meta‐Analysis of Randomized Controlled Trials , 2010, Clinical pharmacology and therapeutics.

[16]  Son Doan,et al.  Integrating existing natural language processing tools for medication extraction from discharge summaries , 2010, J. Am. Medical Informatics Assoc..

[17]  M. Böhm,et al.  Prevention of Atrial Fibrillation by Renin-Angiotensin System Inhibition , 2010 .

[18]  Melissa A. Basford,et al.  Robust replication of genotype-phenotype associations across multiple diseases in an electronic medical record. , 2010, American journal of human genetics.

[19]  Son Doan,et al.  Application of information technology: MedEx: a medication information extraction system for clinical narratives , 2010, J. Am. Medical Informatics Assoc..

[20]  D. Levy,et al.  Prevention of Atrial Fibrillation: Report From a National Heart, Lung, and Blood Institute Workshop , 2009, Circulation.

[21]  Monique M. B. Breteler,et al.  The Rotterdam Study: 2016 objectives and design update , 2015, European Journal of Epidemiology.

[22]  D. Roden,et al.  Development of a Large‐Scale De‐Identified DNA Biobank to Enable Personalized Medicine , 2008, Clinical pharmacology and therapeutics.

[23]  V. Gudnason,et al.  Age, Gene/Environment Susceptibility-Reykjavik Study: multidisciplinary applied phenomics. , 2007, American journal of epidemiology.

[24]  N. Cook Use and Misuse of the Receiver Operating Characteristic Curve in Risk Prediction , 2007, Circulation.

[25]  Stephen S. Cha,et al.  Secular Trends in Incidence of Atrial Fibrillation in Olmsted County, Minnesota, 1980 to 2000, and Implications on the Projections for Future Prevalence , 2006, Circulation.

[26]  L. Fried,et al.  Thyroid status, cardiovascular risk, and mortality in older adults. , 2006, JAMA.

[27]  Thomas Lavergne,et al.  Cost of care distribution in atrial fibrillation patients: the COCAF study. , 2004, American heart journal.

[28]  G. Jensen,et al.  Rising Rates of Hospital Admissions for Atrial Fibrillation , 2003, Epidemiology.

[29]  J. Mckenney,et al.  National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) , 2002 .

[30]  B. Horne,et al.  Statin therapy is associated with reduced mortality across all age groups of individuals with significant coronary disease, including very elderly patients. , 2002, Journal of the American College of Cardiology.

[31]  Simon Stewart,et al.  A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. , 2002, The American journal of medicine.

[32]  S. Grundy,et al.  National Cholesterol Education Program Third Report of the National Cholesterol Education Program ( NCEP ) Expert Panel on Detection , Evaluation , and Treatment of High Blood Cholesterol in Adults ( Adult Treatment Panel III ) Final Report , 2022 .

[33]  D. Singer,et al.  Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. , 2001, JAMA.

[34]  Mark E. Hill,et al.  The Social Security Administration's Death Master File: the completeness of death reporting at older ages. , 2001, Social security bulletin.

[35]  F. Nieto,et al.  Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus , 2000 .

[36]  D S Bell,et al.  Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. , 2000, New England Journal of Medicine.

[37]  O. Benavente,et al.  Antithrombotic Therapy To Prevent Stroke in Patients with Atrial Fibrillation , 1999, Annals of Internal Medicine.

[38]  J. Sowers,et al.  Diabetes and cardiovascular disease. , 1999, Diabetes care.

[39]  R. Collins,et al.  Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. , 1998, The New England journal of medicine.

[40]  D. Levy,et al.  Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. , 1998, Circulation.

[41]  R B D'Agostino,et al.  Impact of atrial fibrillation on mortality, stroke, and medical costs. , 1998, Archives of internal medicine.

[42]  F A Mathewson,et al.  The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. , 1995, The American journal of medicine.

[43]  Scandinavian Simvastatin Survival Study Group Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) , 1994, The Lancet.

[44]  J. Blumenthal,et al.  Quality-of-life assessment in patients with paroxysmal atrial fibrillation or paroxysmal supraventricular tachycardia. , 1994, The American journal of cardiology.

[45]  N J Wald,et al.  By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? , 1994, BMJ.

[46]  R. Kronmal,et al.  The Cardiovascular Health Study: design and rationale. , 1991, Annals of epidemiology.

[47]  Aric Invest The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. The ARIC investigators , 1989 .

[48]  A. Folsom,et al.  The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. The ARIC investigators. , 1989, American journal of epidemiology.

[49]  D J Spiegelhalter,et al.  Probabilistic prediction in patient management and clinical trials. , 1986, Statistics in medicine.

[50]  F. Harrell,et al.  Evaluating the yield of medical tests. , 1982, JAMA.

[51]  W. Kannel,et al.  Diabetes and cardiovascular disease. The Framingham study. , 1979, JAMA.

[52]  W. Kannel,et al.  The Framingham Offspring Study. Design and preliminary data. , 1975, Preventive medicine.

[53]  W. Kannel,et al.  Relation of Body Weight to Development of Coronary Heart Disease: The Framingham Study , 1967, Circulation.

[54]  W. Kannel,et al.  Factors of risk in the development of coronary heart disease--six year follow-up experience. The Framingham Study. , 1961, Annals of internal medicine.